RhumbLine Advisers’s Protalix BioTherapeutics PLX Stock Holding History

RhumbLine Advisers’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$99.4K	Buy	45,817 +1,448	+3%	+$3.59K	﹤0.01%	3410
2025 Q4	$79.9K	Sell	44,369 -20,825	-32%	-$42.6K	﹤0.01%	3543
2025 Q3	$145K	Sell	65,194 -4,602	-7%	-$7.5K	﹤0.01%	3378
2025 Q2	$103K	Buy	+69,796	New	+$143K	﹤0.01%	3514
2024 Q3	–	Sell	-17,666	Closed	-$20.7K	–	4300
2024 Q2	$20.7K	Sell	17,666 -58,789	-77%	-$69.4K	﹤0.01%	3868
2024 Q1	$96.3K	Buy	76,455 +2,769	+4%	+$4.13K	﹤0.01%	3458
2023 Q4	$131K	Sell	73,686 -21,717	-23%	-$33.8K	﹤0.01%	3359
2023 Q3	$158K	Buy	95,403 +6,830	+8%	+$12.3K	﹤0.01%	3277
2023 Q2	$177K	Buy	+88,573	New	+$211K	﹤0.01%	3300

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

RhumbLine Advisers's PLX Position: Q1 2026 in Review

RhumbLine Advisers increased its Protalix BioTherapeutics (PLX) stake by 3.3% in Q1 2026, buying an estimated $3.59K and bringing the position to 45,817 shares worth $99.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3410.

RhumbLine Advisers first reported a position in PLX in Q2 2023 and has held it in 9 quarters since. The position peaked at $177K in Q2 2023. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

RhumbLine Advisers held 45,817 shares of Protalix BioTherapeutics worth $99.4K as of Q1 2026.
RhumbLine Advisers bought 1,448 Protalix BioTherapeutics shares in Q1 2026, an estimated $3.59K.
Protalix BioTherapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3410 holding.
RhumbLine Advisers first reported a position in Protalix BioTherapeutics in Q2 2023 and has held it in 9 quarters since.
RhumbLine Advisers's Protalix BioTherapeutics position peaked at $177K in Q2 2023.
99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.